PEGylated recombinant human hyaluronidase (PEGPH20) pre-treatment improves intra-tumour distribution and efficacy of paclitaxel in preclinical models.
Lavinia MorosiMarina MeroniPaolo UbezioIlaria Fuso NeriniLucia MinoliLuca PorcuNicolò PaniniMarika ColomboBarbara BlouwDavid W KangEnrico DavoliMassimo ZucchettiMaurizio D'IncalciRoberta FrapolliPublished in: Journal of experimental & clinical cancer research : CR (2021)
Remodelling the stroma of HA-rich tumours by depletion of HA with PEGPH20 pre-treatment, is a potentially successful strategy to improve the intra-tumour distribution of anticancer drugs, increasing their therapeutic efficacy, without increasing toxicity.